New low disease activity target defined in SLE

isolated hematuria in sle patients and its association with proteinuria, uri-nary cast and sle disease activity

isolated hematuria and its association with proteinuria, and urinary cast and systemic lupus erythematosus (sle) disease activity, and decision for renal biopsy is a dilemma for physician in sle patients. the aim of this study was to investigate 1. whether isolated hematuria is associated with active sle, 2. to determine duration between hematuria and proteinuria and urinary cast, and 3. to det...

SLE Neuropathy-Anything New?

SLE (systemic lupus erythematosus) is a multisystem autoimmune disorder of unknown aetiology which can present with myriad clinical presentation. The neurological manifestations of SLE consist of central nervous system (CNS) and peripheral nervous system manifestations (PNS). The CNS manifestations are aseptic meningitis, cerebrovascular accidents (stroke), demyelinating disorders, headache, in...

Remission in SLE: closing in on the target.

Over the past decades, the concept of ‘remission’ has emerged as a moniker for the disease state one would ideally like to achieve when a ‘cure’—the ultimate goal of medical intervention—cannot realistically be hoped for. Originally used in oncology to describe the absence of detectable tumour, remission has become an important concept among medical specialties treating autoimmune inflammatory ...

Atherogenesis and Vascular Disease in SLE

Progress in defining clinically meaningful changes for clinical trials in nonrenal manifestations of SLE disease activity

Since the 2002 Dusseldorf meeting, one new agent, Benlysta, has been approved by the US Food and Drug Administration for systemic lupus erythematosus. Experiences from the field in conducting trials of all the agents tested during this period have provided valuable practical insights. There has been incremental progress in defining the minimal clinically important difference (MCID) of key disea...